
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is a clinical stage company with a promising lead product candidate, Revita, that has shown potential to address the root causes of obesity and type 2 diabetes. The recent updates on key trial results and design, including a significant correlation between ablation length and weight maintenance, provide further support for the efficacy and potential of Revita in the market. Taking into consideration the company's strong financials and potential for future growth, it is likely that Fractyl's stock will continue to perform well in the coming years.
Bears say
Fractyl Health is a clinical stage metabolic therapeutics company with promising candidates for treating obesity and T2D, but it faces several challenges, including a lack of significant statistical significance and concerns about weight regain kinetics. The recent announcement of positive results from its REVEAL-1 and REMAIN-1 studies strengthen the potential efficacy and durability of its lead product, Revita. However, the company's financials show no current sources of revenue, and the outcome of its pivotal trial in 2026 will be a crucial factor for its future success.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares